Skip to content

Study · Non-randomized trial · n = 15 · 2003

3 results

Octreotide abolishes the acute decrease in bone turnover in response to oral glucose.

Clowes JA, Allen HC, Prentis DM, Eastell R, Blumsohn A

The Journal of clinical endocrinology and metabolism1 Oct 2003Cited by 85 (Europe PMC)

PMID14557467 (opens in a new tab)DOI10.1210/jc.2002-021447 (opens in a new tab)PepBankPUB-14557467
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialMechanism

    In subjects receiving octreotide infusion, oral glucose caused no significant decrease in bone turnover.

    In plain wordsIn subjects receiving octreotide, bone turnover did not significantly decrease from baseline after oral glucose.

    Peptide
    Octreotide
    Outcome
    No significant changeBone turnover during oral glucose challenge
    Study

    n = 15

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    There was no significant decrease in bone turnover in response to oral glucose during octreotide infusion.
    2 context sentences
    Summary · context
    Fifteen subjects were each studied on four occasions in a randomized, single-blind, crossover study after receiving 1) oral placebo, iv saline; 2) oral glucose, iv saline; 3) oral glucose, iv octreotide; or 4) iv octreotide alone.
    Summary · context
    We measured serum C-terminal telopeptide of type I collagen, urinary N-terminal telopeptide of type I collagen, osteocalcin, procollagen type I N-terminal propeptide, PTH, insulin, ionized calcium, and glucose over 4 h.
  2. 02HumanNon-randomized trialMechanism

    In subjects receiving octreotide alone, all bone turnover markers increased significantly from baseline (P < 0.05).

    In plain wordsIn subjects receiving octreotide alone, bone turnover markers increased from baseline.

    Peptide
    Octreotide
    Outcome
    IncreaseBone turnover markers after octreotide alone
    Study

    n = 15

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Octreotide alone resulted in a significant increase in all bone turnover markers (P < 0.05) and PTH (P < 0.01).
    2 context sentences
    Summary · context
    Fifteen subjects were each studied on four occasions in a randomized, single-blind, crossover study after receiving 1) oral placebo, iv saline; 2) oral glucose, iv saline; 3) oral glucose, iv octreotide; or 4) iv octreotide alone.
    Summary · context
    We measured serum C-terminal telopeptide of type I collagen, urinary N-terminal telopeptide of type I collagen, osteocalcin, procollagen type I N-terminal propeptide, PTH, insulin, ionized calcium, and glucose over 4 h.
  3. 03HumanNon-randomized trialMechanism

    In subjects receiving octreotide alone, PTH increased significantly from baseline (P < 0.01).

    In plain wordsIn subjects receiving octreotide alone, parathyroid hormone increased from baseline.

    Peptide
    Octreotide
    Outcome
    IncreasePTH after octreotide alone
    Study

    n = 15

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Octreotide alone resulted in a significant increase in all bone turnover markers (P < 0.05) and PTH (P < 0.01).
    2 context sentences
    Summary · context
    Fifteen subjects were each studied on four occasions in a randomized, single-blind, crossover study after receiving 1) oral placebo, iv saline; 2) oral glucose, iv saline; 3) oral glucose, iv octreotide; or 4) iv octreotide alone.
    Summary · context
    We measured serum C-terminal telopeptide of type I collagen, urinary N-terminal telopeptide of type I collagen, osteocalcin, procollagen type I N-terminal propeptide, PTH, insulin, ionized calcium, and glucose over 4 h.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.